Effective
and noninvasive cancer diagnosis is
expected to ease the burden of continued increased deaths worldwide.
Herein, we proposed viscosity of the tumor microenvironment as a biomarker
and further develop a versatile optical agent, TBM-V, for monitoring tumor microenvironmental viscosity alterations to
achieve cancer diagnosis, therapeutic effect tracking, and anticancer
drug screening. When in highly viscous media, near-infrared signals
of TBM-V are specifically activated, endowing the probe
with the capacity of avoiding biological autofluorescence and achieving
high signal-to-noise ratio imaging. The results of vascular imaging
disclosed higher fluorescence of the blood vessels in the tumor than
the normal ones, implying tumors being pointed out with brighter fluorescence.
With the assistance of fluorescence imaging technology, TBM-V achieved noninvasively identifying cancer in vivo with high signal-to-noise ratio imaging. In addition,
the capability of TBM-V to evaluate anticancer drug efficacy
with viscosity as a robust biomarker was explored. Furthermore, as
a proof of concept, screening of the anticancer drugs is also realized
through in situ monitoring of the microenvironmental
viscosity fluctuations of the tumor with TBM-V. Note
that this proposed fluorescence imaging method outperforms the clinical
hematoxylin and eosin (H&E) staining assay with the advantageous
features of noninvasive and in vivo characteristics. We expected that this unique strategy will reinvigorate
the continued perfection of the cancer diagnosis systems.